Vea MedIQ en Español
Dupla antiagregação plaquetária breve se associa ao menor sangramento, enquanto o uso estendido se associa ao menor risco de eventos isquêmicos Meta-análise, publicada na revista Circulation, teve...
Revisão sistemática e meta-análise avaliam terapia antiplaquetária dupla após intervenção coronária percutânea com stents farmacológicos
Escrito por: MDHealth em 5 de abril de 2021
3 min de leitura
Referências
Khan SU, Singh M, Valavoor S, Khan MU, Lone AN, Khan MZ, Khan MS, Mani P, Kapadia SR, Michos ED, Stone GW, Kalra A, Bhatt DL. Dual Antiplatelet Therapy After Percutaneous Coronary Intervention and Drug-Eluting Stents: A Systematic Review and Network Meta-Analysis. Circulation. 2020;142(15):1425-1436.
Yin SH, Xu P, Wang B, et al. Duration of dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stent: systematic review and network meta-analysis. BMJ. 2019;365:l2222.
Roccasalva F, Ferrante G. Dual antiplatelet therapy duration after percutaneous coronary intervention with drug-eluting stents: how short can we go? Minerva Cardioangiol. 2020 Sep 29.
Price MJ. Abbreviated Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in High Bleeding Risk Patients: LEADERS-FREE and ONYX ONE. Interv Cardiol Clin. 2020;9(4):441-449.
Serrano Jr. CV, Soeiro AM, Leal TCAT, Godoy LC, Biselli B, Hata LA et al. Posicionamento sobre Antiagregantes Plaquetários e Anticoagulantes em Cardiologia – 2019. Arq Bras Cardiol. 2019; 113(1):111-134.
